Compare GEMI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEMI | TNGX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2025 | N/A |
| Metric | GEMI | TNGX |
|---|---|---|
| Price | $10.23 | $8.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $21.22 | $12.50 |
| AVG Volume (30 Days) | 2.5M | ★ 2.6M |
| Earning Date | 02-15-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $162,529,000.00 | $66,501,000.00 |
| Revenue This Year | $23.92 | $52.80 |
| Revenue Next Year | $93.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.61 | 53.29 |
| 52 Week Low | $9.67 | $1.03 |
| 52 Week High | $45.89 | $11.20 |
| Indicator | GEMI | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.48 |
| Support Level | N/A | $8.45 |
| Resistance Level | N/A | $9.00 |
| Average True Range (ATR) | 0.00 | 0.51 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 29.21 |
Gemini Space Station Inc is engaged on unlocking the next era of financial, creative, and personal freedom. It envisions a future where crypto will redesign the global financial system, the internet, and money in a way that provides greater choice, independence, and opportunity for all. As a trusted bridge between the traditional financial system and the emerging crypto economy, It is providing access for individuals and institutions to a decentralized future that is more open, fair, and secure. Its core exchange product has expanded over time to become a comprehensive platform for its users to engage with the crypto economy, including a derivatives exchange, staking services, an over-the-counter (OTC) trading desk, institutional-grade custody, and others.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.